Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Rossi

Showing results (201-210 of 259) with videos related to

Pageof 26
Sort By:
Annals of Hematology|December 14, 2019
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practiceMassimo Breccia, Claudia Baratè, Giulia Benevolo, et al.
Blood Transfusion = Trasfusione Del Sangue|November 13, 2018
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensusMariasanta Napolitano, Giorgia Saccullo, Marco Marietta, et al.
Blood Cancer Journal|August 6, 2025
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2<sup>V617F</sup> suppression and event-free survival in polycythemia veraTiziano Barbui, Arianna Ghirardi, Victoria Empson, et al.
Annals of Hematology|June 16, 2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosisMassimo Breccia, Luigiana Luciano, Novella Pugliese, et al.
Leukemia|May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Massimo Breccia, Elena M Elli, et al.
Journal of Medical Genetics|January 9, 2007
13q Deletion and central nervous system anomalies: further insights from karyotype-phenotype analyses of 14 patientsLucia Ballarati, Elena Rossi, Maria Teresa Bonati, et al.
British Journal of Haematology|December 18, 2012
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patientsTommaso Za, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|October 11, 2025
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experienceAngela Rago, Francesca Fioritoni, Carmine Liberatore, et al.
Pageof 26

Showing results (201-210 of 259) with videos related to

Sort By:
Pageof 26
Annals of Hematology|December 14, 2019
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practiceMassimo Breccia, Claudia Baratè, Giulia Benevolo, et al.
Blood Transfusion = Trasfusione Del Sangue|November 13, 2018
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensusMariasanta Napolitano, Giorgia Saccullo, Marco Marietta, et al.
Blood Cancer Journal|August 6, 2025
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2<sup>V617F</sup> suppression and event-free survival in polycythemia veraTiziano Barbui, Arianna Ghirardi, Victoria Empson, et al.
Annals of Hematology|June 16, 2019
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosisMassimo Breccia, Luigiana Luciano, Novella Pugliese, et al.
Leukemia|May 28, 2025
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyureaFrancesca Palandri, Massimo Breccia, Elena M Elli, et al.
Journal of Medical Genetics|January 9, 2007
13q Deletion and central nervous system anomalies: further insights from karyotype-phenotype analyses of 14 patientsLucia Ballarati, Elena Rossi, Maria Teresa Bonati, et al.
British Journal of Haematology|December 18, 2012
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patientsTommaso Za, Valerio De Stefano, Elena Rossi, et al.
American Journal of Hematology|January 7, 2010
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemiaValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|July 8, 2009
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutationValerio De Stefano, Tommaso Za, Elena Rossi, et al.
Annals of Hematology|October 11, 2025
Infection events in patients with newly diagnosed multiple myeloma with anti-CD38 monoclonal antibody-based first line regimens: A multicentric Italian experienceAngela Rago, Francesca Fioritoni, Carmine Liberatore, et al.
Pageof 26